{"entity":{"id":"paper-chaarted-nejm-2015","kind":"paper","name":"CHAARTED: chemohormonal therapy in metastatic hormone-sensitive prostate cancer","aka":[],"tldr":"Giving six cycles of docetaxel at the start of hormone therapy for metastatic prostate cancer lengthened survival by over a year in men with high-volume disease, the first trial to show that early chemotherapy helps.","summary":"Phase 3 trial of 790 men with metastatic hormone-sensitive prostate cancer randomised to androgen deprivation alone or with six cycles of docetaxel.\n\nMedian overall survival was 57.6 versus 44.0 months (hazard ratio 0.61) overall, and 49.2 versus 32.2 months in high-volume disease; long-term follow-up showed no benefit in low-volume disease.","asOf":"2026-09-17","links":[{"label":"N Engl J Med 2015","url":"https://doi.org/10.1056/NEJMoa1503747"},{"label":"PubMed","url":"https://pubmed.ncbi.nlm.nih.gov/26244877/"}],"tags":[],"related":["prostate-roadmap","paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","paper-tannock-tax-327-docetaxel-prednisone-nejm-2004"],"cancers":["prostate-mhspc","prostate"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":["chaarted"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":["nejm"],"dependsOn":[],"notes":[],"journal":"New England Journal of Medicine","year":2015,"doi":"10.1056/NEJMoa1503747","pmid":"26244877","authors":"Sweeney CJ, Chen YH, Carducci M, et al.","paperType":"rct","findings":["Median overall survival 57.6 vs 44.0 months; hazard ratio 0.61.","High-volume disease: 49.2 vs 32.2 months; no benefit in low-volume disease on follow-up."],"whatItMeans":"Docetaxel with androgen deprivation is a standard for high-volume metastatic hormone-sensitive prostate cancer, now usually combined with an androgen receptor pathway inhibitor as triplet therapy.","caveats":["Open-label; defined the high-volume criteria (visceral metastases or four or more bone lesions with one beyond the pelvis and spine) used since."],"changedPractice":true,"participants":790},"route":"/key-papers/paper-chaarted-nejm-2015/","neighbours":{"roadmap":[{"id":"prostate-roadmap","kind":"roadmap","name":"Prostate cancer roadmap: from Huggins and the discovery that a cancer can depend on a hormone, through the PSA epidemic and what it cost, the androgen receptor drugs, the DNA repair subset and PSMA, to a 2032 registry watch","route":"/roadmaps/prostate-roadmap/"}],"paper":[{"id":"paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013","kind":"paper","name":"GETUG-AFU 15: androgen deprivation alone or with docetaxel in non-castrate metastatic prostate cancer","route":"/key-papers/paper-gravis-getug-afu-15-docetaxel-lancet-oncol-2013/"},{"id":"paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016","kind":"paper","name":"STOpCaP: docetaxel or bisphosphonates added to standard of care in hormone-sensitive prostate cancer, a systematic review and meta-analysis","route":"/key-papers/paper-vale-stopcap-docetaxel-bisphosphonates-lancet-oncol-2016/"},{"id":"paper-tannock-tax-327-docetaxel-prednisone-nejm-2004","kind":"paper","name":"TAX 327: docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer","route":"/key-papers/paper-tannock-tax-327-docetaxel-prednisone-nejm-2004/"}],"cancer":[{"id":"prostate-mhspc","kind":"cancer","name":"Metastatic hormone-sensitive prostate cancer","route":"/cancers/prostate-mhspc/"},{"id":"prostate","kind":"cancer","name":"Prostate cancer","route":"/cancers/prostate/"}],"trial":[{"id":"chaarted","kind":"trial","name":"CHAARTED (E3805)","route":"/trials/chaarted/"}],"journal":[{"id":"nejm","kind":"journal","name":"New England Journal of Medicine","route":"/journals/nejm/"}]}}